LEGN Earnings Date: Nov 10, 2026 (Estimated) — Legend Biotech Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is LEGN's next earnings date?
Legend Biotech Corporation (LEGN) is expected to report Q3 2026 earnings on Tuesday, November 10, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.01 on revenue of $361.5M.
How did LEGN do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Legend Biotech Corporation posted EPS of $0.16 versus the $0.12 estimate, a beat of 36.0%. Revenue was $387.5M against a $356.0M estimate. The stock's 1-day post-earnings move was +5.7%.
How much does LEGN stock move after earnings?
LEGN beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.3% (up or down) in the day after earnings.
About Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | 0.12 | 0.16 | -36.00% | $387.5M | ✅ Beat | +5.66% | -0.05% | -3.63% |
| 2026-05-12 | Q1 2026 | -0.14 | -0.03 | +78.57% | $305.1M | ✅ Beat | +10.48% | +5.47% | +36.28% |
| 2026-03-10 | Q4 2025 | -0.18 | 0.01 | +105.56% | $306.3M | ✅ Beat | +2.19% | -0.21% | -4.39% |
| 2025-11-12 | Q3 2025 | -0.12 | -0.05 | +58.33% | $272.3M | ✅ Beat | -2.67% | -8.15% | -28.16% |
| 2025-08-11 | Q2 2025 | -0.21 | -0.34 | -61.90% | $255.1M | ❌ Miss | -2.05% | +1.35% | -7.43% |
| 2025-03-11 | Q4 2024 | -0.33 | -0.15 | +54.55% | $186.5M | ✅ Beat | +9.29% | +11.49% | -9.58% |
| 2024-08-09 | Q2 2024 | -0.38 | -0.05 | +86.84% | $186.5M | ✅ Beat | -1.77% | -2.04% | -11.51% |
| 2024-05-13 | Q1 2024 | -0.34 | -0.16 | +52.94% | $94.0M | ✅ Beat | -0.62% | +4.44% | +2.34% |
Showing last 8 quarters.
Revenue by segment & region
By region
FY2025 · $772.7M total · annual
| Segment | Share | Revenue | YoY | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 96.6% | $746.1M | +71.6% | $86.4M | — | $234.7M | $434.7M |
| CHINA | 3.4% | $26.6M | +8212.5% | $3.4M | $328K | $179K | $320K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.